TRVI NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Trevi Therapeutics Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 18.25 USD
4.1% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 32.9% above the Trend Line and sits at 85.6% of its 52-week range. The latest completed week returned 4.1%, after a 1.8% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is bullish with 51/100 conviction, while the latest news-sentiment score is 57/100. Near-term considerations: volume confirmation is below normal; earnings are due in 4d.

Setup score 69 out of 100
Latest Close 18.25 USD 31 Jul 2026
1W Return 4.1% latest completed week
4W Return 1.8% short-term follow-through
12W Return 25.9% quarterly tape
Trend Breadth 100.0% 52 of 52 weeks active
Volume Ratio 0.8x vs 13-week average
What is working
  • The trend backdrop is active with a 86-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 2 reversal markers appear in the recent smart-money tape.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 4.1% Latest completed week; four-week move 1.8%. Indicator stack 100/74 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bullish 51/100 conviction; expected move 9.0%. News sentiment 57/100 62 relevant articles in the latest sentiment read. Event risk 4d Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 32.9% above the Trend Line and sits at 85.6% of its 52-week range. The latest completed week returned 4.1%, after a 1.8% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.9012-week average 0.83

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.90Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers

No recent accumulation markers. 2 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 1.8% over four weeks, 25.9% over 12 weeks, and 149.0% over one year. The current trend has remained active for 86 consecutive weeks.

Performance by holding period

1W4.1%
4W1.8%
12W25.9%
26W74.3%
52W149.0%
Active trend streak86 weeks
Active weeks in one year52
Trend breadth100.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.32Latest activity-pressure read.
Pressure change8.6%Four-week change in activity pressure.
Leadership38.26Latest relative-leadership reading.
RS change-0.6%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 67% Model confidence 64%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength33/100Blend of value, momentum, and quality. Underlying universe rank 68; rank 1 is best.
Value42/100Relative valuation strength. Underlying universe rank 59; rank 1 is best.
Quality41/100Profitability and accounting quality. Underlying universe rank 60; rank 1 is best.
Momentum42/100Medium-term price momentum. Underlying universe rank 59; rank 1 is best.
Growth43/100Revenue and earnings growth. Underlying universe rank 58; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-1.3%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-22.3%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-4.3%
Net share repurchases relative to market value.
Shareholder yield
-4.3%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.4x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

TRVI shows bullish options pressure with a 51/100 conviction score, put-call volume ratio of 0.00, expected move of 9.0%, and Sharemaestro trend signal active.

Conviction51/100
Expected move9.0%
Put/call volume0.00
Pressure100
Speculation3
Volatility63
Trend agreement8
Open options detail
Insider activity5 / 0

5 acquisitions and 0 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment57/100

Weighted news tone is neutral across 62 relevant articles.

18 positive · 42 neutral · 2 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move9.0%Nearest-chain priced movement where available.
52-week drawdown-9.7%Distance below the 52-week high.
13-week volatility7.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher15 of 2611 weeks finished lower.
Best week+21.1%Week of 19 Jun.
Worst week-17.2%Week of 13 Mar.
Latest week+4.1%Week of 31 Jul.

Shape of recent returns

Strong gains13
Modest gains2
Flat weeks0
Modest losses6
Sharp losses5
Recent vol7.0%13-week weekly-return volatility.
Base vol7.7%52-week weekly-return volatility.
Up/down split30/22Count of positive and negative weeks in the 52-week window.
Average skew7.1% / -4.8%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape71/100

Trend, activity pressure, participation, and risk combine to a 71/100 tape read.

 Indicator analysis86/100

Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 12/12.

Activity pressure 0.90; 2 reversal markers Factors38/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 82; Small Cap Core rank 59 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options49/100

TRVI shows bullish options pressure with a 51/100 conviction score, put-call volume ratio of 0.00, expected move of 9.0%, and Sharemaestro trend signal active.

Bullish · Call-side pressure · Expected move 9.0% Sentiment57/100

Weighted news tone is neutral across 62 relevant articles.

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Rating of "Buy" from Analysts Insiders5 / 0

5 acquisitions and 0 disposals in the latest 180-day insider tape.

 Earnings4d

Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202618.25 USD4.1%13.73 USD6.40 USD1.3238.267.7MOn
24 Jul 202617.54 USD-8.0%13.52 USD6.30 USD1.4835.3710.6MOn
17 Jul 202619.07 USD6.9%13.36 USD6.20 USD1.6946.6020.1MOn
10 Jul 202617.84 USD-0.5%13.16 USD6.10 USD1.6333.5213.0MOn
3 Jul 202617.93 USD-1.2%12.99 USD6.00 USD1.2238.4711.2MOn
26 Jun 202618.15 USD5.5%12.84 USD5.90 USD0.7943.5720.1MOn
19 Jun 202617.21 USD21.1%12.68 USD5.80 USD0.4632.1910.4MOn
12 Jun 202614.21 USD6.6%12.47 USD5.70 USD0.2113.545.1MOn
5 Jun 202613.33 USD-5.7%12.38 USD5.63 USD0.349.964.4MOn
29 May 202614.14 USD0.1%12.30 USD5.56 USD0.6112.083.8MOn
22 May 202614.13 USD-0.5%12.22 USD5.48 USD0.7316.106.2MOn
15 May 202614.20 USD-2.1%12.10 USD5.41 USD0.9219.086.6MOn
8 May 202614.50 USD4.5%11.97 USD5.33 USD1.1322.259.2MOn
1 May 202613.87 USD-3.7%11.82 USD5.26 USD0.9724.358.0MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.